Differential expression ofCYP3A12andCYP3A26mRNAs in canine liver and intestine
Authors:
- 16 October 2008
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 38 (10) , 1305-1312
Abstract
The cytochrome P450 (CYP) 3A family is often considered the most important CYP subfamily with regard to drug metabolism in people. Certainly, CYP3A4 contributes to poor oral bioavailability of a number of drugs, and a tremendous amount of effort has been made in attempting to find an appropriate model system to predict the oral bioavailability of candidate drugs. The dog is a species widely used as a preclinical model for the evaluation of drug safety and pharmacokinetics. Compared with other species, little information is available on the tissue distribution of CYP enzymes. The purpose of this study was to determine the level of messenger RNA (mRNA) expression of the canine CYP3A subfamily (CYP3A12 and CYP3A26) in the liver and duodenum. Overall, expression of CYP3A mRNA was greater in the liver than in the duodenum. Hepatic expression of CYP3A26 was greater than CYP3A12 in all dogs, with CYP3A26 comprising 75.2% of the hepatic mRNA CYP3A pool. Conversely, duodenal expression of CYP3A12 was greater than CYP3A26 in all dogs, with CYP3A12 comprising 99.8% of the duodenal mRNA CYP3A pool. In summary, these results represent an important step toward the systematic comparison of human and canine CYP3A enzymes, particularly in relation to oral bioavailability of substrate drugs.Keywords
This publication has 19 references indexed in Scilit:
- Species Differences in In Vitro and In Vivo Small Intestinal Metabolism of CYP3A SubstratesJournal of Pharmaceutical Sciences, 2008
- Drugs as CYP3A Probes, Inducers, and InhibitorsDrug Metabolism Reviews, 2007
- CYTOCHROME P450 GENE INDUCTION IN RATS EX VIVO ASSESSED BY QUANTITATIVE REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION (TAQMAN)Drug Metabolism and Disposition, 2006
- THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”Drug Metabolism and Disposition, 2006
- The effects of inhibiting cytochrome P450 3A, p‐glycoprotein, and gastric acid secretion on the oral bioavailability of methadone in dogsJournal of Veterinary Pharmacology and Therapeutics, 2005
- Selective Inhibition of Dog Hepatic CYP2B11 and CYP3A12The Journal of Pharmacology and Experimental Therapeutics, 2005
- Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivoClinical Pharmacology & Therapeutics, 2005
- SUBSTRATE SPECIFICITY AND KINETIC PROPERTIES OF SEVEN HETEROLOGOUSLY EXPRESSED DOG CYTOCHROMES P450Drug Metabolism and Disposition, 2003
- Evidence for propofol hydroxylation by cytochrome P4502B11 in canine liver microsomes: breed and gender differencesXenobiotica, 2000
- First-pass metabolism of cyclosporin by the gutThe Lancet, 1991